10月13日，Tempus AI盘中下跌5.08%，报67.33美元/股，成交额1.38亿美元。
尽管公司宣布扩展与Moderna、Merck的多年合作以支持个体化癌症疗法intismeran autogene的潜在商业化，但股价仍承压。合作内容涵盖肿瘤组织、血样采集及测序服务支持，财务条款未披露。
与此同时，高管密集减持成为短期情绪压制因素，显示内部资金态度谨慎，叠加生命科学工具板块整体走弱以及行业龙头10x Genomics跌超10%，令该股在消息面利好与筹码面利空之间偏向弱势。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.